Base Metals Investing Mesoblast Trading Update at Annual General Meeting Highlights Continued Strong Growth in Ryoncil® Revenue
Base Metals Investing Mesoblast and BMT CTN to Initiate Pivotal Trial of Ryoncil® as Part of First-Line Regimen in Adults with Severe Acute GVHD Refractory to Steroids
Base Metals Investing Mesoblast to Meet With FDA Next Month to Discuss Rexlemestrocel-L and Opioid Cessation
Base Metals Investing Ryoncil® Receives J-Code From Medicare & Medicaid Services Facilitating Reimbursement and Broader Patient Access
Base Metals Investing Mesoblast Cell Therapy Products are Designated U.S. Origin and Not Subject to Tariffs
Base Metals Investing Successful Commercial Launch of Ryoncil® Highlighted at Global Healthcare Conferences
Homerun Resources Inc. Announces Multi-Process Testing Results for Santa Maria Eterna High-Purity Silica Sand Project
